| 小分子抗新型冠状病毒药物的突破性进展 |
| |
| 引用本文： | 赵喆,张清,葛子若,张伟,陈志海. 小分子抗新型冠状病毒药物的突破性进展[J]. 中国药物警戒, 2022, 0(1): 1-6 |
| |
| 作者姓名： | 赵喆 张清 葛子若 张伟 陈志海 |
| |
| 作者单位： | 首都医科大学附属北京地坛医院感染性疾病临床中心 |
| |
| 基金项目： | 国家重点研发计划(2020YFC0848300);首都卫生发展科研专项项目(2021-1G-4281);教育部2020年长江学者项目。 |
| |
| 摘 要： | 目的 研究蛋白酶抑制剂与依赖RNA的RNA聚合酶抑制剂两种抗新型冠状病毒药物.方法 从作用机制、药代动力学、临床试验等方面对这两类小分子药物进行论述.结果 在诸多抗新型冠状病毒药物中,小分子药物具有易吸收、分子体积小、能够穿透细胞膜、易于大规模工业化生产等优点,是药物研发的重点.在具有抗新型冠状病毒作用的小分子药物中,...
|
| 关 键 词： | 小分子药物 新型冠状病毒肺炎 新型冠状病毒 蛋白酶抑制剂 聚合酶抑制剂 临床试验 |
Giant progress in small molecule antiviral drugs for SARS-CoV-2 |
| |
| ZHAO Zhe,ZHANG Qing,GE Ziruo,ZHANG Wei,CHEN Zhihai. Giant progress in small molecule antiviral drugs for SARS-CoV-2[J]. Chinese JOurnal of Pharmacovigilance, 2022, 0(1): 1-6 |
| |
| Authors: | ZHAO Zhe ZHANG Qing GE Ziruo ZHANG Wei CHEN Zhihai |
| |
| Affiliation: | (Center of Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China) |
| |
| Abstract: | Objective To study anti-SARS-CoV-2 drugs of protease inhibitors and RNA-dependent RNA polymerase inhibitors.Methods The mechanism of action,pharmacokinetics and clinical trials of two kind of drugs are reviewed.Results Small molecule drugs have the advantages of easy absorption,small molecular volume,ability to penetrate cell membrane,and easy large-scale industrial production,which are the focus of drug research and development.In the small-molecule drugs for SARS-CoV-2,breakthroughs have been made in protease inhibitors(such as Paxlovid)that target the viral protein splicing step and RNA-dependent RNA polymerase inhibitors(such as molnupiravir).Conclusion It is expected that these drugs can be widely used in early treatment in the future to reduce the rate of severe illness and mortality. |
| |
| Keywords: | small molecule drugs COVID-19 SARS-CoV-2 protease inhibitor polymerase inhibitor clinical trials |
| 本文献已被 维普 等数据库收录！ |
|
